

 **OLIGOS &
PEPTIDES**
WORLD ASIA 2027

Advancing Oligonucleotide & Peptide Therapeutics from Clinical R&D to Manufacturing in Asia

 23 - 24 March 2027 Sands Expo & Convention Centre, Singapore

PART OF



**BIOPHARMA APAC
CONFEX** BIOPHARMA ASIA PACIFIC
CONFERENCE, EXHIBITION
& AWARDS

 MANUFACTURING  ADC  CDT  CLINICAL TRIALS  TIDES  SUPPLY CHAIN

OFFICIAL EVENT BROCHURE

<https://infohub.imapac.com/opwa-2027>

Table of Contents

About the Event	3
Sponsors & Media Partners	4
Agenda At A Glance	5
Agenda	6
Expected Audience Snapshot	15
Who Should Sponsor?	16
Why Sponsor This Event?	16
Our Past Partners	17
Add to Calendar	18
Registration Form	19
About IMAPAC	21

EVENT CONTACTS

HEAD OF PRODUCTION

Lara Santiago

lara.santiago@imapac.com
+639176210686

BUSINESS DEVELOPMENT MANAGER

Ana Laxamana

ana.laxamana@imapac.com
+6569836132

Nathan Grace Niño

nathan.grace@imapac.com
+6569836134

SENIOR NETWORKING DELEGATE EXECUTIVE

Niti Gupta

niti.gupta@imapac.com
+6569901633

EVENT HIGHLIGHTS

300+
ATTENDEES

120+
COMPANIES

35+
SPEAKERS

DATE & VENUE

23 - 24 March 2027

Sands Expo & Convention Centre
Singapore

CO-LOCATED EVENTS



About the Event

The Oligos & Peptides World Asia 2027 is the region's leading platform dedicated to advancing oligonucleotide and peptide-based therapeutics across the value chain — from early-stage R&D and clinical trials to large-scale manufacturing.

As Asia emerges as a key hub for next-generation therapeutics, the Congress will bring together leaders from biopharma and big pharma, alongside regulatory experts, to exchange insights, explore innovation, and strengthen regional collaboration. Through a carefully curated programme featuring case studies from across APAC, the Congress aims to accelerate development pipelines and drive

manufacturing excellence in oligonucleotide and peptide therapies.

Spanning eight focused sessions, the Oligos & Peptides World Asia 2027 will explore the latest advancements in ASOs, siRNA, and peptide therapeutics; innovative delivery and formulation technologies; and progress in clinical trials and translational research across the region. The programme will also address scalable manufacturing, evolving regulatory frameworks, emerging digital and platform innovations, and best practices in quality and analytical strategies — offering a comprehensive view of Asia's expanding oligonucleotide and peptide ecosystem, from R&D to large-scale production.

Sponsors & Media Partners

EXHIBITOR



Honya Biotech

MEDIA & PUBLICITY



Life Sciences
Review



Business Development Manager:

Ana Laxamana · ana.laxamana@imapac.com · +6569836132
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

Agenda At A Glance

CONFERENCE DAY 1 23TH MARCH 2027, WEDNESDAY		CONFERENCE DAY 2 24TH MARCH 2027, THURSDAY	
Leadership Panel RNA & Oligonucleotides Landscape in APAC		Clinical Development & Regulatory Excellence	
MORNING TEA, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING			
Peptide Therapeutics 2.0 Beyond Metabolic Diseases		Manufacturing, CMC & Commercial Scale- Up	
LUNCH, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING			
Delivery Technologies & Tissue Targeting		Quality, Analytics & Regulatory Innovation	
AFTERNOON TEA, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING			
Oligonucleotide-Peptide Conjugates & Novel Modalities		Convergence of RNA, Peptides & Next- Generation Therapeutics	
END OF CONFERENCE DAY 1		END OF CONFERENCE	
ASIA PACIFIC BIOPHARMA EXCELLENCE AWARDS 2027 GALA DINNER			

Day 1

Tuesday, 23 March 2027

8:50

IMAPAC's Opening Remarks

8:55

Chairman's Welcome Address

RNA & Oligonucleotides Landscape in APAC

9:00

Leadership Panel: Scaling Asia's Leadership in Oligonucleotide & Peptide Therapeutics

- What will position APAC as the next global hub for oligonucleotide and peptide therapeutics?
- How can industry accelerate commercialization while strengthening regional manufacturing capacity?
- Which partnerships are critical to build a globally competitive innovation ecosystem?

9:50

Scaling Manufacturing for Oligonucleotide–Peptide Conjugates

- Scaling synthesis and conjugation processes
- Ensuring manufacturing consistency
- Overcoming production challenges
- Building scalable pathways for clinical supply



Reserved for Solution Provider

10:05

Building Asia-Based RNA Development & Manufacturing Ecosystems

- Strengthening regional capabilities from discovery through GMP manufacturing
- Reducing dependency on fragmented global development networks
- Accelerating technology transfer and capability building across APAC
- Creating integrated pathways from research to commercial supply

10:30

Morning Tea, Exhibition Viewing & 1-1 Networking

Peptide Therapeutics 2.0: Beyond Metabolic Diseases

11:15

High-Throughput Peptide Screening for Oncology, Immunology & Rare Diseases

- Building screening strategies for complex disease targets
- Identifying functional hits from diverse peptide libraries
- Evaluating potency, selectivity and stability early
- Prioritising candidates for further development

11:40

From Peptide Hit to Drug Candidate: Optimising Stability, Selectivity & Developability

- Improving peptide stability and half-life
- Optimising selectivity and target engagement
- Addressing developability challenges early
- Supporting efficient progression from hit discovery to candidate selection

**Reserved for Solution Provider**

11:55

Beyond GLP-1: The Next Wave of Peptide Therapeutics

- Expanding peptides into oncology, immunology, neurological and rare diseases
- Targeting undruggable and intracellular targets
- Advancing multi-agonist and multispecific peptide platforms
- Differentiating peptides from antibodies and small molecules

12:20

Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking

Delivery Technologies & Precision Tissue Targeting

2:05

PANEL DISCUSSION

The Next Frontier in Precision Delivery for Oligonucleotide Therapeutics

Questions:

- Which delivery technologies show the strongest potential for extrahepatic oligonucleotide delivery?
- How are companies tackling delivery to difficult tissues including CNS, muscle and immune cells?
- What approaches are emerging to overcome endosomal escape and improve intracellular activity?
- What will it take to move next-generation delivery platforms from promising preclinical data into clinical development?

2:35

Breaking Biological Barriers: Next-Generation Delivery for Tissue-Targeted Peptide Therapeutics

- Engineering peptides to overcome membrane, epithelial and physiological barriers that restrict tissue exposure.
- Advancing receptor-mediated and ligand-directed strategies for cell- and tissue-specific uptake.
- Optimising biodistribution while reducing off-target exposure and systemic toxicity.
- Translating delivery performance from preclinical models into clinically relevant tissue exposure and efficacy.



Reserved for Solution Provider

2:50

Beyond the Injection: Engineering Oral & Non-Invasive Delivery for Peptide Therapeutics

- Overcoming enzymatic degradation, poor permeability and low bioavailability across oral and mucosal routes.
- Evaluating permeation enhancers, nanoparticles, lipid systems and other formulation technologies.
- Connecting peptide molecular design with route-of-administration and formulation strategy.
- Closing the gap between promising bioavailability data and scalable, patient-friendly products.

3:25

Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Networking**Oligonucleotide-Peptide Conjugates & Novel Modalities**

4:10

Panel Discussion: Beyond GalNAc: Peptide-Oligonucleotide Conjugates for the Next Frontier of Targeted Delivery

- Breaking the liver barrier: enabling extrahepatic delivery to muscle, CNS and other difficult-to-reach tissue
- Engineering peptide ligands for greater cell and tissue specificity, uptake and intracellular trafficking
- Optimising linker chemistry, conjugation architecture and oligonucleotide design for stability and potency
- Translating promising delivery platforms into clinically viable and scalable therapeutics

4:40

Conjugate by Design: Engineering the Next Generation of Peptide-Oligonucleotide Therapeutics

- Designing the optimal peptide-linker-oligonucleotide architecture for therapeutic performance
- Balancing potency, selectivity, stability, PK/PD and intracellular release
- Comparing cell-penetrating, receptor-targeting and tissue-specific peptide strategies
- Applying computational and AI-enabled approaches to accelerate conjugate design and candidate selection



Reserved for Solution Provider

4:55

Conjugates at Scale: Manufacturing the Next Generation of Oligonucleotide-Peptide Therapeutics

- Scaling synthesis and conjugation while maintaining yield, purity and batch consistency
- Tackling purification challenges associated with conjugated and non-canonical molecules
- Controlling critical quality attributes, impurities and conjugation-related heterogeneity
- Building scalable and commercially viable CMC strategies from clinical development onward

5:20

Chairman's Closing Remarks

5:30

END OF DAY 1 CONFERENCE

6:00

Cocktails & Networking

6:30

Asia-Pacific Biopharma Excellence Awards 2027 Gala Dinner

Day 2

8:50

IMAPAC's Opening Remarks

8:55

Chairman's Welcome Address

Clinical Development & Regulatory Excellence

9:00

FDA & EMA Regulatory Readiness for Oligonucleotide & Peptide Therapeutics: From Early Development to Global Approval

- Navigating regulatory expectations for novel oligonucleotide and peptide modalities
- Designing clinical development strategies that support regulatory decision-making
- Addressing evidence requirements for novel mechanisms and emerging modalities
- Building regulatory strategies across the U.S., Europe and APAC

9:25

From First-in-Human to Approval: De-Risking Clinical Development for Oligos & Peptides

- Designing efficient FIH and early-phase trials for novel oligonucleotide and peptide modalities.
- Translating preclinical PK/PD, biodistribution and toxicology into dose selection and escalation strategies.
- Identifying meaningful biomarkers and clinical endpoints to demonstrate early proof of mechanism and efficacy.
- Building regulatory evidence packages that support faster progression from Phase I through pivotal development.



Reserved for Solution Provider

9:40

Dose Matters: Optimising Exposure, Target Engagement & Therapeutic Window in Oligo and Peptide Trials

- Translating tissue exposure and target engagement into rational clinical dose selection.
- Applying PK/PD modelling to understand dose-response relationships and therapeutic windows.
- Managing prolonged pharmacological effects and complex dosing intervals in oligonucleotide programmes.
- Integrating emerging clinical data to optimise dose and regimen ahead of pivotal development.

Day 2

10:05

From Accelerated Approval to Global Launch: Late-Stage Development & Lifecycle Strategy for Oligos and Peptides

- Designing pivotal programmes around meaningful clinical endpoints and regulatory expectations.
- Establishing confirmatory evidence strategies for accelerated or conditional approval pathways.
- Integrating clinical, CMC and regulatory readiness as programmes move toward commercialisation.
- Planning post-marketing commitments, real-world evidence and lifecycle expansion into new indications.

10:30

Morning Break, Exhibition Viewing & 1-1 Networking

Manufacturing, CMC & Commercial Scale-Up

11:15

Tech Transfer Without the Turbulence: Moving Oligo & Peptide Processes into GMP Manufacturing

- Defining the critical process and analytical knowledge required for successful technology transfer
- Bridging gaps between process development, analytical, manufacturing, quality and external CDMO teams
- Establishing comparability when processes, equipment or manufacturing sites change
- Using risk-based transfer strategies to shorten timelines while protecting product quality and supply

11:40

Scaling the Chemistry: Optimising SPPS & Oligonucleotide Synthesis for Cost, Yield and Throughput

- Overcoming scale limitations in solid-phase peptide and oligonucleotide synthesis
- Optimising coupling efficiency, reagent consumption, cycle times and resin/support utilisation
- Reducing solvent intensity, waste generation and cost of goods at commercial volumes
- Evaluating where liquid-phase, hybrid and alternative synthesis technologies can outperform conventional approaches



Reserved for Solution Provider

Day 2

11:55

Breaking the Solid-Phase Ceiling: Enzymatic, Hybrid & Next-Generation Manufacturing for Oligos and Peptides

- Assessing where enzymatic and hybrid synthesis can overcome conventional solid-phase limitations
- Comparing scalability, selectivity, productivity, cost and environmental footprint
- Addressing new CMC and regulatory considerations introduced by alternative manufacturing technologies
- Defining what is required to transition emerging synthesis platforms from proof-of-concept to GMP and commercial production

12:20

Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking

Quality, Analytics & Regulatory Innovation

2:05

From Development to GMP: Building Phase-Appropriate Analytical Control Strategies That Scale

- Designing analytical methods early with commercial scalability and GMP readiness in mind
- Defining CQAs and translating them into robust release and in-process controls
- Moving methods from development laboratories into QC without losing robustness
- Aligning analytical development, process development, QC and CMC teams to reduce late-stage surprises

2:30

AI-Powered Analytical Development: Can Automation Accelerate Release of Complex Therapeutics?

- Applying AI and machine learning to analytical data interpretation
- Automating data review while maintaining human oversight
- Strengthening data integrity and traceability
- Moving toward faster, risk-based QC and batch release



Reserved for Solution Provider

2:45

Beyond the Main Peak: Advanced Impurity Profiling & Control Strategies for Oligos and Peptides

- Identifying process-, product- and degradation-related impurities across increasingly complex molecules
- Applying LC-MS/HRMS and orthogonal analytical techniques to resolve closely related species
- Linking impurity origin and formation pathways to CQAs and process controls
- Establishing scientifically justified impurity thresholds and specifications for regulatory submissions

3:10

Analytics for the Next Generation: Characterising Conjugated, Modified & Non-Canonical Oligos and Peptides

- Tackling heterogeneity introduced by conjugation, chemical modifications and novel structures
- Combining chromatographic, mass spectrometric and orthogonal methods for deeper characterization
- Defining molecule-specific CQAs for increasingly complex modalities
- Developing platform analytical approaches while retaining flexibility for modality-specific risks

3:35

Afternoon Tea, Exhibition Viewing & 1-1 Networking

Convergence of RNA, Peptides & Next-Generation Therapeutics

4:20

Beyond ADCs: APCs & RDCs for the Next Wave of Precision Therapeutics

- Advancing APCs and RDCs as emerging targeted therapeutic platforms
- Expanding applications beyond traditional oncology
- Optimising targeting, payload design and therapeutic precision
- Translating novel conjugates from platform innovation to the clinic

4:25

From Breakthrough Platform to Global Product: What Will It Take to Commercialize Next-Generation Therapeutics?

- Identifying technologies with the strongest potential to reach commercial scale
- Overcoming delivery, CMC, regulatory and market-access barriers
- Building global development and manufacturing strategies from Asia
- Turning platform innovation into sustainable product pipelines



Reserved for Solution Provider

4:40

AI-Enabled mRNA Therapeutics: From Precision Design to Clinical Translation

- Applying AI and in silico approaches to optimise therapeutic mRNA design
- Integrating computational prediction with biological and immunological validation
- Advancing precision mRNA approaches for therapeutic applications
- Translating next-generation mRNA platforms into clinical-stage programmes



Wonil Kim
CSO, Aston Sci

5:05

Accelerating RNA Therapeutic Discovery: High-Throughput Screening, Design & Safety

- High-throughput screening strategies for RNA therapeutic discovery
- Compound design and optimisation to accelerate candidate selection
- Integrating in vitro safety assessment during early lead development
- Improving the quality and confidence of preclinical RNA candidates



Dr. Pratik Dave
Senior Scientist, Roche

5:30

Asia's Next Wave of RNA & Peptide Innovation - What Will Win the Race to Market?

Questions:

- Which therapeutic modality will define the next phase of RNA and peptide innovation?
- Where should industry focus next: delivery, clinical validation, manufacturing or regulatory strategy?
- Can Asia become the global launchpad for next-generation therapeutics rather than simply a development and manufacturing hub?

6:15

Chairman's Closing Remarks

6:20

END OF DAY 2 CONFERENCE

Expected Audience Snapshot

80%

ATTENDANCE FROM APAC REGION

80%


DECISION MAKERS

BY PROFILE

Cell Therapy Companies & Biopharma (Asia) **45%**




Cell Therapy Companies & Biopharma (International) **15%**



Big Pharma **10%**




CRO & CMO/CDMO **12%**




Government & Academic Research Institutes **7%**



Technology & Service Providers **8%**




Others **3%**



BY JOB TITLE


CEOs, CSOs, CTOs & President **20%**



VPs, Directors, Head of Cell & Gene Therapy Development & Regenerative Medicine **30%**




Manager & Head of Research & Development **20%**




Research Scientist & Professor **15%**



Marketing, Sales and Business Development **10%**



Others **5%**



BY GEOGRAPHY

10% Europe & USA

15% China & Taiwan

20% South Korea

10% Japan

15% Hong Kong, India & Philippines

30% Indonesia, Malaysia, Singapore & Thailand

Who Should Sponsor?

Bioprocessing Equipment Vendors

Clinical Research Organization (CRO's)

Diagnostics & Analytical Tools

Lab Equipment/Sterilization, Purification/Equipments (Columns, Centrifuges, Homogenizers, Chromatography Columns)

Logistic Service Providers

Engineering/Facility/Design

International CMOS's

Cell Lines

Cold Chain

Cell Culture Media/Lab Equipments

Others (Drug Distributors, Disinfection, Refrigerator, ETC)

Why Sponsor This Event?

Thought Leadership

Present Your Expertise to the Biopharma Industry's Key Stakeholders through a Variety of Available Speaking Packages.

Host a Panel Discussion

Moderate a panel discussion including one representative from your company with 3 representatives from the end user side to share views on a current industry topic

Duration: 45 minutes

Showcase Your Solutions to Educate the Market

Join in for dedicated CMO & CRO Showcases for German Market

Branding

Emphasize on your Message by Marketing and Promoting Alongside the Event

Networking & Lead Generation

Gain Exclusive Access to Contacts of High Profile Attendees through Intimate Networking Opportunities

Business Development Manager:

Ana Laxamana · ana.laxamana@imapac.com · +6569836132
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

Our Past Partners



Business Development Manager:

Ana Laxamana · ana.laxamana@imapac.com · +6569836132
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

MARK YOUR CALENDAR

Save the Date

23–24 **MAR**
2027 Sands Expo & Convention Centre

Oligos & Peptides World Asia 2027

ALL IMAPAC EVENTS



Explore Our Full Event Calendar

Discover all upcoming and future IMAPAC events across Asia-Pacific — biopharmaceutical conferences, summits, and exhibitions for the year ahead.



OR ADD THIS EVENT TO YOUR CALENDAR

**Google Calendar**

One-click add to Gmail

**Outlook Calendar**

Add to Microsoft Outlook

**Scan to Register**

Open camera, point at code, instant registration access.

Or click the QR to open registration directly.

CATEGORY	EARLY BIRD (By 3 Oct 2026)	REGISTRATION (By 5 Dec 2026)	STANDARD (By 6 Feb 2027)	FINAL CALL
BIOPHARMA, ACADEMIC & RESEARCH — BASED IN ASIA (APAC)				
2-Day Conference Pass Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,495	SGD 1,695	SGD 1,895	SGD 2,095
BIOPHARMA, ACADEMIC & RESEARCH — BASED OUTSIDE OF ASIA				
2-Day Conference Pass Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,995	SGD 2,195	SGD 2,395	SGD 2,595
BIG PHARMA, SOLUTION / SERVICE / TECHNOLOGY PROVIDERS & CDMO/CMO				
2-Day Conference Pass Business Development, Marketing & Sales profiles	SGD 2,995	SGD 3,195	SGD 3,395	SGD 3,595
BRING YOUR TEAM - Group Discount				
Asia & International Biopharma - Buy 2, Get 3 passes - Buy 3, Get 5 passes Limited to professionals in the "BUYER" profile working in Process Development, R&D, QC & Assurance, Manufacturing Heads, Engineering, Upstream, Downstream or Analytical in Big Pharmas, International / Asian Biopharmas, and Academic & Research Institutes. INNER CIRCLE Speaker referrals and professionals working in the same organisation as our speakers are entitled to a 15% discount. - Access to all conference proceedings for up to 30 days. - Site Tour Package is applicable only with the purchase of a conference pass.				
Standard Package Group Discount				
3 Delegates Save 10% 5 Delegates Save 20% 6+ Delegates Save 25%				

EVENT VENUE



Sands Expo & Convention Centre
Singapore
23 - 24 March 2027

3 EASY WAYS TO REGISTER

Online
Visit:
<https://www.imapac.com/events/oligonucleotides-peptides-world-asia-congress-2027#register>

Telephone
+65 6983 6140 (SG) / +44 161 552 8507 (UK)

Mail
Cheque payable to IMAPAC Pte Ltd,
36 Robinson Road, #02-01
068877
Singapore
Cheque payable to IMAPAC UK Ltd,
77 Farringdon Road, Farringdon, London
EC1M 3JU
United Kingdom

YOUR DETAILS

Name

Job Title

Address

Postcode

Tel

Email

Your primary business

Authorising Manager

Organization

Country

Fax

Authorising manager signature

PAYMENT DETAILS

Payment is due immediately upon receipt of this registration form if you pay by credit card or 3 working days after your receipt of payment notification. Non-credit card payment will incur an additional US\$100 (Bank handling fee)

I want to pay: ☐ Credit Card ☐ Bank Transfer ☐ Cheque

Offline credit card: ☐ Visa ☐ MasterCard ☐ American Express

Online credit card payment: Please register at <https://www.imapac.com/events/oligonucleotides-peptides-world-asia-congress-2027#register>

Name on Card

Expiry Date (MM/YY)

Card Number

CVC Code

Signature

TERMS & CONDITIONS

Payment & Registration
Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice. Registration will not be confirmed until full payment has been received. Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you. Staff at the event will request a credit card guarantee for delegates without proof of payment.

Ticket Classification
All registrations are reviewed to ensure correct classification. Biopharma tickets are reserved for professionals employed by pharmaceutical or biopharmaceutical companies that develop, own or commercialise therapeutic drug products. Service, Solution and Technology Provider tickets apply to organisations offering services, platforms, technologies, equipment, consultancy or manufacturing services to the industry (including CROs, CDMOs, vendors, consultants and suppliers). Purchasing an incorrect ticket does not guarantee entry. IMAPAC retains full discretion to deny access, reclassify registrations and issue an invoice for the price difference. Incorrect ticket purchases under an inappropriate classification are not eligible for refunds under any circumstances.

Cancellation & Substitution Policy
Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference, attendees will receive a full credit note towards a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time in writing at no extra charge. In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference, or in the event of postponement by IMAPAC, towards the rescheduled date. Credit notes remain valid for twelve months.

Changes to Conference & Agenda
IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Changes to the agenda will be updated on our website as soon as possible.

Data Protection
The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.



**BIOPHARMA APAC
CONFEX** BIOPHARMA ASIA PACIFIC
CONFERENCE, EXHIBITION
& AWARDS

MANUFACTURING

ADC

CGT

CLINICAL TRIALS

TIDES

SUPPLY CHAIN

THIS EVENT IS PART OF

Biopharma APAC Confex 2027

Connecting Leaders. Anchoring Partnerships.

Biopharma APAC Confex is Asia-Pacific's leading biopharma gathering, bringing together 2,000+ attendees and 700+ companies across co-located conferences spanning biologics manufacturing, clinical trials, ADCs, cell & gene therapy, TIDES, and supply chain innovation — supporting collaboration, knowledge sharing, and strategic partnerships across the region.

2000+

ATTENDEES

700+

COMPANIES

250+

SPEAKERS

72+

NETWORKING HOURS

CO-LOCATED CONFERENCES

**ADC ASIA
CONGRESS 2027**

**BIOLOGICS
MANUFACTURING ASIA 2027**

**BIOSUPPLY
CHAIN ASIA 2027**

**CLINICAL TRIALS
FESTIVAL ASIA 2027**

**CELL & GENE
THERAPY WORLD
ASIA 2027**

**OLIGOS &
PEPTIDES
WORLD ASIA 2027**



23–24 March 2027

Sands Expo & Convention Centre, Singapore

biopharmaapacconfex.com

A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS.

01 B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.

Create an engaging experience for your audiences, explore our B2B Events Solutions.

02 360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

Tap into our pool of audience that spans across various sub-sectors and regions critical in the burgeoning APAC biopharmaceutical sector.

03 DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

Customize the dashboard based on your needs. Drill down to the data you need using custom views.

04 CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

With access to a database of 60,000+ life science professionals. We conduct research with a highly-qualified audience.

05 REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

[Learn More →](#)



HELPING THE GLOBAL BIOPHARMACEUTICAL INDUSTRY

Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the

core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

WEBSITE

imapac.com

EMAIL

info@imapac.com

IMAPAC PTE LTD

36 Robinson Road, #02-01
Singapore 068877
+65 6983 6140

IMAPAC UK LTD

77 Farringdon Road, Farringdon
London EC1M 3JU, United Kingdom
+44 161 552 8507

CONNECT WITH US

LINKEDIN

@imapac

X

@imapac

FACEBOOK

ImapacPteLtd